[Federal Register: October 17, 2002 (Volume 67, Number 201)]
[Page 64128-64129]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Science Board to the Food and Drug Administration Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Science Board to the Food and Drug 
    General Function of the Committee: The Board shall provide advice 
primarily to the Commissioner and the Senior Associate Commissioner for 
Science and Health and other appropriate officials on specific complex 
and technical issues as well as emerging issues within the scientific 
community. Additionally, the Board will provide advice to the agency on 
keeping pace with technical and scientific evolutions in the fields of 
regulatory science, formulating an appropriate research agenda, and 
upgrading its scientific and research facilities to keep pace with 
these changes. It will also provide the means for critical review of 
agency sponsored intramural and extramural scientific research 
    Date and Time: The meeting will be held on October 25, 2002, 8 a.m. 
to 4:30 p.m.
    Location: 5630 Fishers Lane, rm. 1066, Rockville, MD 20857.
    Contact Person: Susan Bond, Office of the Commissioner (HF-33), 
Food and Drug Administration, rm. 17-35, 5600 Fishers Lane, Rockville, 
MD 20852, 301-827-6687, or e-mail: sbond@oc.fda.gov, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12603.

[[Page 64129]]

 Please call the Information Line for up-to-date information on this 
    Agenda: The Board will hear and discuss counter terrorism 
initiatives at FDA with emphasis on those initiatives from: The Center 
for Food Safety and Applied Nutrition, the new Office of Cellular and 
Gene Therapy in the Center for Biologics Evaluation and Research, 
current research and efforts in the pregnancy labeling initiative, an 
update of the pharmaceutical manufacturing initiative from The Center 
for Drug Evaluation and Research, and an update of the management 
oversight of products.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by October 18, 
2002. Open committee discussion will be held from 8 a.m. to 1 p.m.; an 
open public hearing will be held from 1 p.m. to 2 p.m.; and an open 
committee discussion will be held from 2 p.m. to 4:30 p.m. Oral 
presentations from the public will be scheduled between approximately 1 
p.m. and 2 p.m. Time allotted for each presentation may be limited. 
Those desiring to make formal oral presentations should notify the 
contact person before October 18, 2002, and submit a brief statement of 
the general nature of the evidence or arguments they wish to present, 
the names and addresses of proposed participants, and an indication of 
the approximate time requested to make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Susan Bond at least 
7 days in advance of the meeting.
    FDA regrets that it was unable to publish this notice 15 days prior 
to the October 25, 2002, Science Board to the Food and Drug 
Administration Advisory Committee Meeting. Because the agency believes 
there is some urgency to bring these issues to public discussion and 
qualified members of the Science Board to the Food and Drug 
Administration Advisory Committee were available at this time, the 
Commissioner concluded that it was in the public interest to hold this 
meeting even if there was not sufficient time for the customary 15-day 
public notice.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: October 10, 2002.
Linda Arey Skladany,
Senior Associate Commissioner for External Relations.
[FR Doc. 02-26472 Filed 10-11-02; 4:26 pm]